Novo Nordisk to Discontinue Victoza Marketing Across EU/EEA by 2026.

Novo Nordisk to discontinue marketing of Victoza across EU/EEA by end of 2026. Novo Nordisk specializes in diabetes and obesity treatment products, with 93.6% of net sales from this category. The company has operations in Europe, the US, China, and other regions.

Novo Nordisk, a leading global pharmaceutical company, has announced its decision to discontinue the marketing of Victoza across the European Union (EU) and European Economic Area (EEA) by the end of 2026. This move comes as the company focuses on its more advanced diabetes and obesity treatment products, such as Ozempic and Wegovy. The decision underscores Novo Nordisk's strategic shift towards innovative therapies and its commitment to improving patient outcomes.

Victoza, a GLP-1 receptor agonist, has been a key product for Novo Nordisk, contributing significantly to its revenue. However, with the advent of newer and more effective treatments, such as Ozempic, the company has decided to phase out Victoza in the EU/EEA region. This strategic decision aligns with Novo Nordisk's long-term vision of providing cutting-edge treatments for diabetes and obesity.

The company's Chief Scientific Officer, Martin Holst Lange, stated that while Victoza has been a valuable drug, it is time to focus on the more advanced and effective therapies. He emphasized that the discontinuation of Victoza will not impact the company's ongoing clinical trials and research efforts to improve the treatment of diabetes and obesity.

Novo Nordisk's operations in the EU/EEA region will continue to focus on its newer and more effective products, such as Ozempic and Wegovy. These products have shown promising results in clinical trials and have the potential to revolutionize the treatment of diabetes and obesity.

The decision to discontinue Victoza is part of Novo Nordisk's broader strategy to innovate and improve patient outcomes. The company's focus on newer and more effective therapies will continue to drive its growth and profitability in the coming years.

References:

[1] https://www.ainvest.com/news/novo-nordisk-tests-ozempic-20-alzheimer-risk-2509/
[2] https://www.novonordisk.com/
[3] https://www.mk.co.kr/en/it/11409727
[4] https://www.reuters.com/sustainability/boards-policy-regulation/eu-regulator-flags-surge-online-sales-counterfeit-weight-loss-drugs-2025-09-03/
[5] https://www.globenewswire.com/news-release/2025/09/05/3145087/0/en/Novo-Nordisk-to-present-new-semaglutide-data-on-food-noise-body-composition-and-cardiovascular-benefits-as-well-as-pipeline-data-at-the-EASD-diabetes-congress.html